Skip to main content
SpringerLink
Log in

Preconditioning the human myocardium: Recent advances and aspirations for the development of a new means of cardioprotection in clinical practice

  • Reviews
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Ischemic preconditioning has been shown to be one of the most powerful means of protecting the myocardium from ischemic injury in experimental animal models, although the mechanism is incompletely understood. In this review we discuss the evidence for preconditioning occurring in ischemic syndromes in humans, whether the human myocardium can be preconditioned, and whether preconditioning would have a place as a therapeutic tool in clinical practice. Some studies evaluating patients after acute myocardial infarction have shown a better outcome in patients reporting angina before the onset of the infarction, but this is not a universal finding, and it is difficult to exclude other confounding factors, such as collateral flow, from influencing the results. More controlled prospective studies have evaluated patients undergoing percutaneous transluminal coronary angioplasty and have found less ST-segment change and less reported angina during the second balloon inflation when compared with the first. Again, it is impossible to completely exclude other causes for this effect, but the dependence on mechanisms that are known to be important for preconditioning in animal models does suggest the phenomena are the same. Further experiments using isolated human atrial muscle have shown that human myocardium can be preconditioned and that the mechanisms involved are similar to those elucidated in animal models (adenosine, protein kinase C, and ATP-dependent potassium channels). In clinical medicine preconditioning is most likely to benefit patients when it is used to protect against the ischemia induced by cardiac surgery. In this respect, a study has shown that in patients undergoing coronary artery bypass grafts, the reduction in ATP occurring during the first ischemic period is attenuated in those given an ischemic preconditioning protocol beforehand. Despite these advances, it is likely that the full potential of preconditioning in clinical practice will not be realized until the whole mechanism of protection is understood and a safe pharmacological “preconditioning” agent becomes available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Murray CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium.Circulation 1986;74:1124–1136.

    PubMed  Google Scholar 

  2. Walker DM, Yellon DM. Ischemic preconditioning: From mechanisms to exploitation.Cardiovasc Res 1992;26:734–739.

    PubMed  Google Scholar 

  3. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.Circulation 1993;88:1264–1272.

    PubMed  Google Scholar 

  4. Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia.Circ Res 1993;72:1293–1299.

    PubMed  Google Scholar 

  5. Yellon DM, Baxter GF. A “second window of protection” or delayed preconditioning phenomenon: Future horizons for myocardial protection?J Mol Cell Cardiol 1995;27:1023–1034.

    Article  PubMed  Google Scholar 

  6. Baxter GF, Goma FM, Yellon DM. Duration of the second window of protection following ischaemic preconditioning in the rabbit (abstr).J Mol Cell Cardiol 1995;27:A162.

    Google Scholar 

  7. Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: Reperfusion-induced arrhythmias.Am J Physiol 1987;253:H1470–1476.

    PubMed  Google Scholar 

  8. Lawson CS, Coltart DJ, Hearse DJ. “Dose”-dependency and temporal characteristics of protection by ischaemic preconditioning against ischaemia-induced arrhythmias in rat hearts.J Mol Cell Cardiol 1993;25:1391–1402.

    PubMed  Google Scholar 

  9. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode.Circ Res 1990;66:913–931.

    PubMed  Google Scholar 

  10. Cohen MV, Liu GS, Downey JM. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits.Circulation 1991;84:341–349.

    PubMed  Google Scholar 

  11. Jenkins DP, Pugsley WB, Yellon DM. Ischaemic preconditioning in a model of global ischaemia: Infarct size limitation, but no reduction of stunning.J Mol Cell Cardiol 1995;27:1623–1632.

    PubMed  Google Scholar 

  12. Baxter GF, Marber MS, Patel V, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning.Circulation 1994;90:2993–3000.

    PubMed  Google Scholar 

  13. Cave AC, Collis CS, Downey JM, Hearse DJ. Improved functional recovery by ischaemic preconditioning is not mediated by adenosine in the globally ischaemic rat heart.Cardiovasc Res 1993;27:663–668.

    PubMed  Google Scholar 

  14. Liu Y, Ytrehus K, Downey JM. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning in the rat.J Mol Cell Cardiol 1994;26:661–668.

    PubMed  Google Scholar 

  15. Speechly-Dick ME, Mocanu M, Yellon DM. Protein kinase C. Its role in ischemic preconditioning in the rat.Circ Res 1994;75:586–590.

    PubMed  Google Scholar 

  16. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.Circ Res 1992;70:223–233.

    PubMed  Google Scholar 

  17. Schulz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine.Am J Physiol 1994;267:H1341-H1352.

    PubMed  Google Scholar 

  18. Parratt JR, Kane KA. KATP channels and ischaemic preconditioning.Cardiovasc Res 1994;28:783–787.

    PubMed  Google Scholar 

  19. Cohen MV, Downey JM. Ischaemic preconditioning: Can the protection be bottled?Lancet 1993;342:6.

    PubMed  Google Scholar 

  20. Speechly-Dick ME, Baxter GF, Yellon DM. Ischaemic preconditioning protects hypertrophied myocardium.Cardiovasc Res 1994;28:1057–1061.

    PubMed  Google Scholar 

  21. Kloner RA, Yellon DM. Does preconditioning occur in patients?J Am Coll Cardiol 1994;24:1133–1142.

    PubMed  Google Scholar 

  22. Lawson CS. Does ischaemic preconditioning occur in the human heart?Cardiovasc Res 1994;28:1461–1466.

    PubMed  Google Scholar 

  23. Muller DWM, Topol EJ, Califf RM, et al. Relationship between antecedent angina pectoris and short term prognosis after thrombolytic therapy for acute myocardial infarction.Am Heart J 1990;119:224–231.

    PubMed  Google Scholar 

  24. Barbash GI, White HD, Modan M, Van de Werf F. Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: Experience gleaned from the international tissue plasminogen activator/streptokinase mortality trial.J Am Coll Cardiol 1992;20:36–41.

    PubMed  Google Scholar 

  25. Ruocco NA, Bergelson BA, Jacobs AK, Frederick MM, Faxon DP, Ryan TJ. Invasive versus conservative strategy after thrombolytic therapy for acute myocardial infarction in patients with antecedent angina.J Am Coll Cardiol 1992;20:1445–1451.

    PubMed  Google Scholar 

  26. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate of preconditioning?Circulation 1995;91:37–47.

    PubMed  Google Scholar 

  27. Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size. A role for ischemic preconditioning.Circulation 1995;91:291–297.

    PubMed  Google Scholar 

  28. Fujita M, Sasayama S, Ohno A, Nakajima H, Asanoi H. Importance of angina for development of collateral circulation.Br Heart J 1987;57:139–143.

    PubMed  Google Scholar 

  29. Rentrop K, Cohen M, Blanke H, Phillips R. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects.J Am Coll Cardiol 1985;5:587–592.

    PubMed  Google Scholar 

  30. Ovize M, Kloner RA, Hale SL, Przyklenk K. Coronary cyclic flow variations “precondition” ischemic myocardium.Circulation 1992;85:779–789.

    PubMed  Google Scholar 

  31. Shizukuda Y, Mallet RT, Lee S-C, Downey HF. Hypoxic preconditioning of ischemic canine myocardium.Cardiovasc Res 1992;26:534–542.

    PubMed  Google Scholar 

  32. Marber MS, Joy MD, Yellon DM. Is warm-up in angina ischaemic preconditioning?Br Heart J 1994;72:213–215.

    PubMed  Google Scholar 

  33. Deutch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrman HC, Laskey WL. Adaptation to ischemia during percutaneous transluminal coronary angioplasty.Circulation 1990;82:2044–2051.

    PubMed  Google Scholar 

  34. Cribier A, Korsatz L, Koning R, et al. Improved myocardial ischemic response and enhanced collateral circulation with repetitive coronary occlusion during angioplasty: A prospective study.J Am Coll Cardiol 1992;20:578–586.

    PubMed  Google Scholar 

  35. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.Circulation 1994;90:700–705.

    PubMed  Google Scholar 

  36. Tomai F, Gea F, Gaspardone A, et al. Blockade of A1-adenosine receptors prevents myocardial preconditioning in man (abstr).Eur Heart J 1994;15(Suppl):553.

    Google Scholar 

  37. Tomai F, Crea F, Gaspardone A, et al. Mechanisms of cardiac pain during coronary angioplasty.J Am Coll Cardiol 1993;22:1892–1896.

    PubMed  Google Scholar 

  38. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium.Lancet 1993;342:276–277.

    Article  PubMed  Google Scholar 

  39. van der Vusse GJ, van der Veen FM, Flameng W, et al. A biochemical and ultrastructural study on myocardial changes during aorto-coronary bypass surgery: St. Thomas Hospital Cardioplegia verses intermittent aortic cross-clamping at 34 and 25°C.Eur Surg Res 1986;18:1–11.

    Google Scholar 

  40. Lee HT, Sanchola VT, Reed GE, Belkin RN, La Faro RJ. Preconditioning of human myocardium with adenosine during cardiac surgery (abstr).Circulation 1994;90(Suppl 4):1–48.

    PubMed  Google Scholar 

  41. Walker DM, Walker JM, Pattison CW, Pugsley WB, Yellon DM. Preconditioning in isolated superfused human muscle.J Mol Cell Cardiol 1995;27:1349–1357.

    PubMed  Google Scholar 

  42. Speechly-Dick ME, Pattison CW, Pugsley WB, Yellon DM. Hypoxic preconditioning of human right atrial trabecula involves a protein kinase C-dependent mechanism.Br J Pharmacol 1995;114(Suppl 1):2498.

    Google Scholar 

  43. Speechly-Dick ME, Pattison CW, Pugsley WB, Grover GJ, Yellon DM. The ATP-sensitive potassium channel: Its role in ischaemic preconditioning in human atrial trabecula (abstr).J Mol Cell Cardiol 1995;27:A154.

    Google Scholar 

  44. Ikonomidis JS, Tumiati LC, Weisel RD, Mickle DAG, Li R-K. Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischaemia.Cadiovasc Res 1994;28:1285–1291.

    Google Scholar 

  45. Cohen MV, Yang X-M, Downey JM. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning.Circ Res 1994;74:998–1004.

    PubMed  Google Scholar 

  46. Tsuchida A, Thompson R, Olsson R, Downey JM. The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischemic preconditioning in rabbit hearts.J Mol Cell Cardiol 1994;26:303–312.

    Article  PubMed  Google Scholar 

  47. Theroux P, Quimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina.N Engl J Med 1988;319:1105–1111.

    PubMed  Google Scholar 

  48. Cave AC, Hearse DJ. Ischemic preconditioning and contractile function: Studies with normothermic and hypothermic global ischemia.J Mol Cell Cardiol 1992;24:1113–1123.

    Article  PubMed  Google Scholar 

  49. Kolocassides KG, Galinanes M, Hearse DJ. Ischemic preconditioning, cardioplegia or both?J Mol Cell Cardiol 1994;26:1411–1414.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Hatter Institute for Cardiovascular Studies, Department of Academic and Clinical Cardiology, University College London Hospitals, Grafton Way, WC1E 6AU, London, UK

    David P. Jenkins, Stephen E. Steare &  Derek M. Yellon

Authors
  1. David P. Jenkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen E. Steare
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Derek M. Yellon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jenkins, D.P., Steare, S.E. & Yellon, D.M. Preconditioning the human myocardium: Recent advances and aspirations for the development of a new means of cardioprotection in clinical practice. Cardiovasc Drug Ther 9, 739–747 (1995). https://doi.org/10.1007/BF00879866

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00879866

Key Words

Search

Navigation